摘要
在基因工程抗体中,Fab类(Fabs)抗体有许多优势,如相对分子质量小、组织分布特异性强和免疫原性低等,使Fab类抗体成为近几十年来的研究热点。除了应用较广泛的体外酶消化法外,多种表达系统(如大肠杆菌和昆虫等)皆用于Fab类抗体的获得,其中大肠杆菌表达的系统研究最为彻底,且已经应用于制备Fab类临床药物。目前已经有赛妥珠单抗等6种Fab类抗体药物通过了美国FDA申请并上市,并有多种Fab类药物正处于临床试验阶段。本文分别对Fab类抗体的基本结构及特点、Fab类抗体的生成、表达和提高产量的策略、临床应用的研究进展进行介绍。
In genetic engineering antibodies,Fabs antibodies have many advantages,such as lower relative molecular mass, specific tissue distribution and lower immunogenicity, which have made Fabs antibodies the research hotspot for the past few decades. Besides the widely used enzymatic generation, multiple expression systems which include E. coli. and insects are used in the generation of Fabs antibodies. E. coli. expression system is most thoroughly explored and has been used in the preparation of clinical Fabs drugs. There are six Fab drugs that have been approved by FDA, such as certolizumabpegol and many Fabs are still in clinical research. This review discusses the recent research progress of Fabs drugs, including Fabs′ structure and characteristics, the generation and expression of Fabs, strategies to increase production and clinical applications, with the emphasis on generation, expression and clinical applications.
出处
《国际药学研究杂志》
CAS
CSCD
2014年第3期318-324,347,共8页
Journal of International Pharmaceutical Research
